GlobeNewswire

Craft Brewer Funky Buddha Joins Constellation Brands

Dela

Constellation Strengthens its Position in High-End Beer

VICTOR, N.Y., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today its purchase of Florida-based Funky Buddha Brewery, reinforcing its strategy to lead the high-end beer segment in the United States. Funky Buddha is the fastest growing craft brewery in Florida, and produces bold craft beers made with high quality ingredients. It has an award-winning portfolio led by Floridian Hefeweizen and Hop Gun IPA. Funky Buddha joins Constellation's Craft & Specialty Beer Group in the beer division.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3f69f036-65a3-427c-89a4-1e46e59a89ff

Funky Buddha Lounge & Brewery was founded in 2010 in Boca Raton, Florida, by husband and wife Ryan and Giani Sentz. As the demand for Funky Buddha's beers skyrocketed, Ryan and Giani invited Ryan's brother KC Sentz, and his wife Melissa Sentz, to join the business. In 2013, the Sentz family started Funky Buddha Brewery, located in the heart of Oakland Park's burgeoning Culinary Arts District. At 54,000 sq ft and with a capacity of 45,000 BBLs, Funky Buddha Brewery is South Florida's largest craft microbrewery by size and volume, and is Florida's busiest tap room by beer sales.

"We chose to partner with Constellation because we saw an alignment in vision and felt they gave us the greatest opportunity for growth and development," said Funky Buddha Head Brewer and President Ryan Sentz. "Constellation and Funky Buddha share a lot of the same ideals and passion for philanthropy, entrepreneurship and the art of craft beer. At the end of the day, we just really like the people we have met within the organization, each of whom share our dedication to making outstanding beer."

2016 was a breakout year for Funky Buddha Brewery, receiving five gold medals in RateBeer's Best Awards. When it came to the Best Beers by Style, they dominated the Imperial Porter category with three gold medals for Morning Wood, Wide Awake It's Morning, and Last Buffalo in the Park. Maple Bacon Coffee Porter and Last Snow Coconut Coffee Porter both received gold medals in the Best Beers by Style Porter category. Maple Bacon Coffee Porter also was a Winner of the World Beer Cup 2016 Gold Medal in the Specialty Beer category. And as the engine behind these high-quality beers, the Funky Buddha team was recognized by placing in the Top 100 Brewers category.

"Adding a fantastic regional brand such as Funky Buddha to our craft beer portfolio, along with Ballast Point, advances our strategy in continuing to lead the high-end beer segment," said Paul Hetterich, executive vice president and president of the beer division at Constellation Brands. "The Sentz family has created a culture of bold creativity, innovation and entrepreneurship. Those qualities, combined with our beer division's market reach, distributor partnerships, consumer insights, and our craft expertise within Ballast Point, will help nurture and develop Funky Buddha's distinctive brand."

Constellation Brands and Funky Buddha Brewery's team of employees will continue to work together, with Ryan and KC Sentz running the day-to-day operations. Funky Buddha's standard of brewing will remain unchanged, delivering the same culinary-style, creative beer consumers and craft beer enthusiasts celebrate today.

Terms of the transaction were not disclosed.

About Constellation Brands
Constellation Brands (NYSE:STZ) (NYSE:STZ.B), a Fortune 500® company, is a leading international producer and marketer of beer, wine and spirits with operations in the U.S., Mexico, New Zealand, Italy and Canada. Constellation is the No. 3 beer company in the U.S. with high-end, iconic imported brands such as Corona Extra, Corona Light, Modelo Especial, Modelo Negra and Pacifico. The company's beer portfolio also includes Ballast Point, one of the most awarded craft brewers in the U.S. In addition, Constellation is the world leader in premium wine, selling great brands that people love, including Robert Mondavi, Clos du Bois, Kim Crawford, Meiomi, Mark West, Franciscan Estate, Ruffino and The Prisoner. The company's premium spirits brands include SVEDKA Vodka, Casa Noble Tequila and High West Whiskey.

Based in Victor, N.Y., the company believes that industry leadership involves a commitment to brand building, our trade partners, the environment, our investors and to consumers around the world who choose our products when celebrating big moments or enjoying quiet ones. Founded in 1945, Constellation has grown to become a significant player in the beverage alcohol industry with more than 100 brands in its portfolio, about 40 wineries, breweries and distilleries, and approximately 9,000 talented employees. We express our company vision: to elevate life with every glass raised. To learn more, visit www.cbrands.com.

About Funky Buddha
Founded in 2010 in Boca Raton, Florida, Funky Buddha Brewery® is committed to producing bold craft beers that marry culinary-inspired ingredients with time-honored technique. Its lineup includes year-round brews Floridian Hefeweizen and Hop Gun IPA, along with specialty releases such as Last Snow and the highly sought after Maple Bacon Coffee Porter. Its Oakland Park production brewery opened in June 2013 and distributes draught and bottled beer to retail outlets throughout Florida.

Forward-Looking Statements 
This news release contains forward-looking statements. The word "expect" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Those statements may relate to Constellation Brands' business strategy, future operations, prospects, plans and objectives of management, as well as information concerning expected actions of third parties. All forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by the forward-looking statements. All forward-looking statements speak only as of the date of this news release. Constellation Brands undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

In addition to risks associated with ordinary business operations, the forward-looking statements contained in this news release are subject to other risks and uncertainties disclosed from time to time in Constellation Brands, Inc.'s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended Feb. 28, 2017, which could cause actual future performance to differ from current expectations.

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

CONTACTS
Constellation Brands                                            
Amy Martin                                                              
585-678-7141 / amy.martin@cbrands.com            
Jamie Stein
312-873-9317 / jamie.stein@cbrands.com
Funky Buddha
John Linn
954-440-0046 / john@funkybuddhabrewery.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Constellation Brands, Inc via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum